HighTower Advisors’s Bristol-Myers Squibb BMY Stock Holding History

HighTower Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,600	Closed	-$2.88K	–	3694
2025 Q3	$2.88K	Buy	+2,600	New	+$121K	﹤0.01%	3743
2024 Q1	–	Sell	-200	Closed	-$341	–	3646
2023 Q4	$341	Buy	+200	New	+$10.5K	﹤0.01%	3587
2018 Q2	–	Sell	-68,200	Closed	-$375K	–	2252
2018 Q1	$375K	Buy	+68,200	New	+$4.39M	﹤0.01%	1564
2017 Q3	–	Sell	-83,000	Closed	-$108K	–	2242
2017 Q2	$108K	Buy	83,000 +28,600	+53%	+$1.56M	﹤0.01%	1951
2017 Q1	$104K	Buy	+54,400	New	+$2.98M	﹤0.01%	1867
2016 Q2	–	Sell	-300	Closed	-$555K	–	1791
2016 Q1	$555K	Buy	+300	New	+$18.9K	﹤0.01%	1328

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HighTower Advisors's BMY Position: Q2 2026 in Review

HighTower Advisors reduced its Bristol-Myers Squibb (BMY) stake by 2.3% in Q2 2026, selling an estimated $1.53M and leaving 1,126,721 shares worth $64.9M. The position accounts for 0.06% of the portfolio, ranked #304.

HighTower Advisors first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $117M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

HighTower Advisors held 1,126,721 shares of Bristol-Myers Squibb worth $64.9M as of Q2 2026.
HighTower Advisors sold 26,606 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.53M.
Bristol-Myers Squibb made up 0.06% of HighTower Advisors's portfolio in Q2 2026, its #304 holding.
HighTower Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
HighTower Advisors's Bristol-Myers Squibb position peaked at $117M in Q2 2022.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.